That's kind of why we got excited about this is
you've got a compound that's got a known performance
effect.
Well-studied Sanford Burnham Prebys published a
number of great clinical papers on its ability to
activate
HNF4α
but yet why has the industry lagged in
turning this into a clinical candidate?
Or turning this into an ingredient of choice for the industry?
And the heart of that problem lies in
it's only available in vanishingly small amounts in
nature so it doesn't present itself as a compound
to be to be farmed
or a compound to be sourced. You have to
produce it - but it was difficult to produce.
Until now.
That's amazing!
